Sermorelin: the complete research guide.

Sermorelin is a 29-amino-acid copy of the active end of GHRH, the hormone that tells your pituitary to release growth hormone. It held FDA approval as Geref from 1997 to 2008. It doesn't now, and we found no randomized adult trial published since 2020.

What is sermorelin?

Sermorelin is a synthetic copy of the first 29 amino acids of native GHRH. The full hypothalamic peptide is 44 residues long. The first 29 carry the entire receptor-binding region, so this short fragment reproduces the full pharmacology of the parent hormone. No fatty acid. No engineered protective group. Just the active N-terminal domain of GHRH.

Serono developed it in the 1980s. The FDA approved it in 1997 as Geref for pediatric growth hormone deficiency. In 2008, Serono's successor pulled it from the U.S. market. The reason was commercial. Small patient population, small revenue. It wasn't a safety withdrawal.

For the next decade, U.S. pharmacies could compound sermorelin under prescription. Recent FDA actions have tightened that channel, as Mendias and Awan documented in 2026.

In the GHRH-analog family, sermorelin is the original. Here's the family tree:

• Sermorelin: the unmodified parent. Half-life 10–20 minutes.
• Tesamorelin: adds a fatty-acid tail that blocks an enzyme called DPP-IV. Half-life 26–38 minutes. The only family member with current FDA approval.
• CJC-1295: further structural tweaks for stability.
• CJC-1295 with DAC: adds an albumin-binding group. Half-life jumps to 6–8 days.

Each generation traded duration for complexity. Sermorelin's only modern advantage, if it has one, is the shape of the response. Its brief GH rise looks more like native pulsatile secretion than the sustained elevation CJC-1295 with DAC produces.

How does sermorelin actually work?

Pituitary GH release mechanism

Sermorelin binds the GHRH receptor on anterior pituitary somatotrophs, the cells that make GH. That binding raises intracellular cAMP, activates protein kinase A, and triggers pulsatile release of stored growth hormone. The pattern mirrors what your body does on its own.

Because sermorelin acts one step upstream of GH, the normal hypothalamic feedback system stays intact and can damp the response. That system is somatostatin plus rising IGF-1. It's why Memdouh and colleagues in 2021 describe GHRH analogs as a more "physiologic" approach than injecting GH itself.

Extrapituitary GHRH receptor expression

Early models held that GHRH receptors sat only in pituitary tissue. Later work found receptor expression in lung, heart, pancreas and several tumor-derived cell lines, per Condor Capcha and colleagues and Louzada and colleagues, both in 2023.

What those off-target sites do in humans is still unclear. The available data come from animal models or from structurally related analogs, not from sermorelin itself.

Pancreatic protection (early-stage)

A 2023 PNAS study in mice and human islets used a sermorelin-like analog called MR-409 in a type 1 diabetes model. Louzada and colleagues reported preserved beta-cell mass, less cell death and better insulin secretion.

Beta cells are the pancreatic cells that make insulin. We'd read that finding as analog-adjacent and mechanism-validating, not a human result.

Anti-tumor signal (early-stage)

A 2021 drug-screening study by Chang and colleagues flagged sermorelin as a candidate against recurrent glioma. Confusingly, GHRH antagonists, drugs that block the same receptor, are in development as anti-cancer agents too.

A 2025 paper by Gesmundo and colleagues showed those antagonists make lung cancer cells more sensitive to radiation. So agonists and antagonists both show activity, in different cancers. Our honest read: the biology is tissue-specific, and "this is a cancer-promoting target" is too simple to be right.

Dosing context in the research literature

No FDA-approved sermorelin product exists today, and no modern randomized trial has established an adult dose. We can only give you historical reference points, from the Geref label and published pharmacokinetic work.

• Pediatric GHD (Geref label): the approved protocol used approximately 30 mcg/kg subcutaneously once daily in diagnostic and therapeutic studies.
• GH stimulation testing (historical): a single 1 mcg/kg IV bolus with GH measurements at 15, 30, 60, 90, and 120 minutes post-administration was used in diagnostic protocols.
• Adult off-label published literature: compounding pharmacy protocols described in the literature have cited 200–500 mcg subcutaneously once daily. A 2026 review notes these protocols lack RCT validation (Mendias & Awan, 2026).

Because sermorelin works through an intact hypothalamic-pituitary feedback axis, the usual cycling rationale is weaker here. That rationale is receptor downregulation, and it applies to injected GH. No published trial has compared continuous against intermittent sermorelin protocols.

What does the research actually show?

Here's where the honest story matters. Sermorelin has a longer human track record than almost any other unapproved peptide, with 11 years of FDA approval from 1997 to 2008. The catch is that the modern adult evidence is empty.

• Pediatric GHD (settled): Geref's FDA approval rested on trials showing sermorelin stimulates GH well enough to diagnose and treat pediatric growth hormone deficiency. The pharmacology is uncontested.
• Adult body composition and senescence endpoints: 0 RCTs (2020–2026). A 2026 review in Sports Medicine places sermorelin among unapproved peptides where the claimed benefits are mechanism-based, not trial-validated (Mendias & Awan, 2026).
• Pancreatic beta-cell protection: the sermorelin-like analog MR-409 preserved beta-cell mass in mice with streptozotocin-induced diabetes (Louzada et al., 2023). Preclinical, not human.
• Anti-glioma signal: sermorelin came out of a drug-screen for recurrent glioma (Chang et al., 2021). Hypothesis-generating.
• Hypogonadism context: a 2020 narrative review groups sermorelin with other GH-releasing drugs for possible roles in low-testosterone management (Sinha et al., 2020). Conceptual, not interventional.
• Anti-doping detection: labs can reliably detect sermorelin and its metabolite fragments in urine and blood (Memdouh et al., 2021).

Sermorelin

29 aa GHRH 1-29 Parent compound

Sermorelin is on our catalog roadmap — not yet stocked at Peptriva. The closest currently available reference compound in our catalog is tesamorelin, the stabilized GHRH analog cited in the same family of studies in this review. Lab-verified identity and purity.

Browse the catalog

What about stacking?

The only stack with even mechanistic logic is sermorelin plus a GHRP. Growth hormone-releasing peptides are a different family working on a different receptor. The human-outcome evidence is still limited.

Sermorelin combined with ipamorelin (a combination studied in the literature)

Sermorelin acts at the GHRH receptor. Ipamorelin acts at the ghrelin receptor. Because the two pathways are independent, the GH responses were expected to add up. Compounding-pharmacy literature describes people using both, but we found no controlled trial confirming the combination beats either one alone.

Sermorelin versus the modern GHRH analogs

In published comparisons, later-generation analogs have largely displaced sermorelin. Tesamorelin carries the only current FDA approval in the class. CJC-1295 lasts far longer.

Half-life is the differentiating variable. Sermorelin's runs roughly 10–20 minutes, producing a brief pulse-like GH rise close to natural secretion. Longer-acting variants produce a sustained plateau instead. No controlled trial has shown the pulse pattern is actually better.

What are the side effects?

Commonly reported

• Injection-site reactions: brief redness, mild swelling, or itching at the site. The most common effect.
• Transient flushing: warmth or facial flushing within minutes of injection. Usually gone within an hour.
• Mild headache.
• Vivid dreams or altered sleep: GHRH plays a role in deep sleep, so this tracks.

Less commonly reported

• Mild swelling, joint stiffness, tingling: secondary to GH elevation; consistent with effects observed with high-dose GH replacement in published trials.
• Reduced insulin sensitivity: GH is counter-regulatory to insulin; sustained GH elevation has been reported to blunt insulin action in study participants with baseline metabolic risk factors.
• Carpal tunnel-like symptoms: reported in cohorts where IGF-1 remained above the reference range for extended periods.

Rare or theoretical concerns

• Tumor biology: GHRH receptors live in some tumors, and sustained IGF-1 elevation is a theoretical cancer concern for the whole GH-axis class. The picture is complicated. The 2021 drug-screen study showed sermorelin fighting glioma cells (Chang et al., 2021), and GHRH-blocking drugs are being developed as cancer treatments (Gesmundo et al., 2025). The biology runs in both directions.
• Long-term safety data is missing. No controlled long-term safety study exists for modern adult use. That's the honest statement about sermorelin's risk profile in 2026.

What's the legal and FDA status?

The FDA approved sermorelin as Geref in 1997 for pediatric growth hormone deficiency. In 2008, the manufacturer pulled it. It was a commercial decision, driven by a small patient pool and low revenue, not a safety withdrawal. No FDA-approved sermorelin product has existed since.

From 2008 on, 503A and 503B compounding pharmacies supplied sermorelin under prescription for off-label use. The FDA has recently tightened that channel, per Mendias and Awan in 2026. third-party tested sermorelin remains legal to sell in the U.S. when labeled Research Use Only.

• FDA (U.S.): Geref discontinued 2008. No approved product. Compounding restrictions in place.
• EMA (EU): not approved.
• Health Canada: not approved.
• Research compound sale (U.S.): legal when labeled Research Use Only.

Is sermorelin banned by WADA?

Yes. Sermorelin sits on the WADA Prohibited List in Section S2, which covers peptide hormones and growth factors. It's banned in and out of competition.

Labs detect sermorelin's metabolite fragments with validated mass-spectrometry methods. That work is documented by Memdouh and colleagues in 2021 and González-López and colleagues in 2023.

Sermorelin's short half-life won't hide it from a drug test. Published research confirms metabolite fragments persist after the parent compound clears. MLB, NFL, NHL, NBA, FINA, UCI and the NCAA all prohibit it, and validated mass-spectrometric detection methods sit in the peer-reviewed literature.

Sermorelin

Roadmap ≥99% pure (when stocked) Lyophilized

Sermorelin (GHRH 1-29) is the unmodified parent peptide of the GHRH analog family. It's on Peptriva's catalog roadmap but not yet stocked. The closest available reference compound today is tesamorelin — the stabilized analog with the only currently-FDA-approved indication in the GHRH family. Each lot ships with a third-party CoA from an ISO 17025 lab.

Learn more

Frequently asked questions

What is sermorelin?

Sermorelin is a synthetic 29-amino-acid peptide matching the first 29 residues of native growth hormone-releasing hormone, or GHRH. It binds GHRH receptors on anterior pituitary somatotrophs and stimulates pulsatile endogenous GH release. The FDA approved it as Geref in 1997 for pediatric growth hormone deficiency. The manufacturer discontinued it in 2008 for commercial reasons.

Is sermorelin FDA-approved?

No, not currently. Geref was the approved sermorelin product, discontinued in 2008 for commercial reasons, not safety. Since then only compounding pharmacies have supplied sermorelin under prescription. The FDA has recently tightened that channel.

How does sermorelin compare to tesamorelin and CJC-1295?

All three act at the same GHRH receptor. Sermorelin is the unmodified parent with a 10–20 minute half-life. Tesamorelin adds a fatty-acid moiety that extends half-life to 26–38 minutes and is the only GHRH analog with current FDA approval, for HIV-associated lipodystrophy. CJC-1295 modifies the scaffold further, and the DAC variant binds albumin for a multi-day half-life.

What dosing has been described in the sermorelin literature?

The Geref pediatric label used approximately 30 mcg per kilogram once daily. Published adult off-label protocols describe 200–500 mcg subcutaneously once daily, timed to the natural nocturnal GH pulse. We found no recent randomized trial supporting any specific adult dose.

Is sermorelin banned by WADA?

Yes. It is on the Prohibited List in Section S2 and banned in and out of competition. Published mass-spectrometric methods can detect sermorelin and its characteristic metabolite fragments in biological samples.

What adverse effects have been reported in studies?

Published reports describe injection-site reactions, transient flushing, mild headache and altered sleep in study participants. Less commonly reported effects include mild edema, joint stiffness and changes in insulin sensitivity. We found no long-term controlled safety data in adults at all.

Is third-party tested sermorelin available in the U.S.?

There is no FDA-approved sermorelin product. Compounding pharmacies have historically supplied it under prescription, though the FDA has tightened that route. third-party tested sermorelin is legal to sell in the U.S. when labeled Research Use Only. That's the only channel you'll find it in now.